Pharmaceutical executives are getting almost daily calls from White House Staff and senior figures at agencies such as the Commerce Department, Dawn Kopecki, Jarrett Renshaw, Ernest Scheyder and Sabrina Valle of Reuters reports, citing two sources familiar with the matter. During these calls, the White House asked Eli Lilly (LLY) to produce more insulin, Pfizer (PFE) to sell more of its cancer drug Ibrance and cholesterol drug Lipitor, and AstraZeneca (AZN) to consider a new headquarters in the U.S., the two sources added. Additionally, the Trump administration is pursuing deals in up to 30 industries, with the fast-paced dealmaking meant to deliver political wins for the president before the 2026 midterm elections, the sources added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Closing Bell Movers: Bentley Systems up 5% on S&P MidCap 400 entry
- Analysts Reaffirm Buy Ratings on Pfizer Stock (PFE) after Trump Pricing Deal
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- Closing Bell Movers: Nike rallies 4% after earnings beat and guidance